Therapeatic Efficacy of Decitabine on Low and Moderate-Risk MDS Patients and the Prognostic Factors.
10.7534/j.issn.1009-2137.2020.01.036
- Author:
Hua-E SHU
1
;
Teng FANG
2
Author Information
1. Department of Hematology, The People's Hospital of Chongqing Kaizhou District, Chongqing 405400, China.
2. Department of Hematology, The People's Hospital of Chongqing Kaizhou District, Chongqing 405400, China,E-mail: fangteng75@126.com.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2020;28(1):214-217
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy of decitabine in the treatment of patients with low-risk and moderate-risk myelodysplastic syndrome (MDS) and to analyze the prognostic factors.
METHODS:A retrospective study was conducted on 47 patients with low and moderate risk MDS treated with decitabine in our hospital. The course of treatment was 20 mg/(m·d)×5 d injected subcutaneously for 28 d as a course of treatment. After 3 to 4 courses of treatment, the therapeutic response and survival prognostic factors of patients were evaluated.
RESULTS:According to the revised IWG standard, 18 patients (38.3%) achieved CR, 13 patients (27.7%) achieved PR, 7 patients (14.9%) showed hematological improvement, 7 patients (14.9%) died of pulmonary infection or myelosuppression, 2 patients transformed into acute myeloid leukemia. The median survival time of MDS patients was 26 months. The overall effective rate of decitabine regimen was 80.9% (38/47). The independent poor prognostic factors for survival were high IPSS grade, long course of MDS, early treatment for MDS, and elder.
CONCLUSION:The long-term efficacy of decitabine in the treatment of low and moderate-risk MDS is definite. The clinical factors before treatment may predict the efficacy of decitabine in the treatment of MDS.
